Effect of liver dysfunction on circulating sclerostin

Journal of Bone and Mineral Metabolism

Volumn 32, Issue 5, 2014, Pages 545-549

  Rhee, Yumie ^a   Kim, Won Jin ^a   Han, Ki Jun ^b   Lim, Sung Kil ^a   Kim, Se Hwa ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

Author keywords

Child Pugh class; Liver cirrhosis; Sclerostin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CREATININE; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SEX DIFFERENCE; BLOOD; GENETIC MARKER; MIDDLE AGED; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; YOUNG ADULT;

ADULT; AGED; BONE MORPHOGENETIC PROTEINS; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84904203848     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-013-0524-z     Document Type: Article

References (28)

1. Collier J (2007) Bone disorders in chronic liver disease. Hepatology 46:1271–1278
2. Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice Committee (2003) AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125:941–966
3. Nakchbandi IA, van der Merwe SW (2009) Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 6:660–670
4. Foresta C, Schipilliti M, Ciarleglio FA, Lenzi A, D’Amico D (2008) Male hypogonadism in cirrhosis and after liver transplantation. J Endocrinol Invest 32:470–482
5. Guañabens N, Parés A, Mariñoso L, Brancós MA, Piera C, Serrano S, Rivera F, Rodés J (1990) Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 85:1356–1362
6. Stellon AJ, Webb A, Compston J, Williams R (1987) Low bone turnover state in primary biliary cirrhosis. Hepatology 7:137–142
7. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J (2005) Sclerostin is a delayed secreted products of osteocytes that inhibits bone formation. FASEB J 19:1842–1844
8. Baron R, Rawadi G (2007) Targeting the Wnt/β-catenin pathway to regulate bone formation in the adults skeleton. Endocrinology 148:2635–2643
9. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887
10. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26:373–379
11. Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A (2012) Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 97:148–154
12. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248–2253
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the esophagus for bleeding esophageal varices. Br J Surg 60:646–649
14. González-Reimers E, Martín-González C, de la Vega-Prieto MJ, Pelazas-González R, Fernández-Rodríguez C, López-Prieto J, Alvisa-Negrín J, Santolaria-Fernández F (2013) Serum sclerostin in alcoholics: a pilot study. Alcohol Alcohol 48:278–282
15. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997
16. Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S (2011) Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26:27–34
17. Lapauw B, Vandewalle S, Taes Y, Goemaere S, Zmierczak H, Collette J, Kaufman JM (2013) Serum sclerostin levels in men with idiopathic osteoporosis. Eur J Endocrinol 168:615–620
18. García-Fontana B, Morales-Santana S, Varsavsky M, García-Martín A, García-Salcedo JA, Reyes-García R, Muñoz-Torres M (2013) Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporos Int [Epub ahead of print] doi 10.1007/s00198-013-2462-y
19. Bannister P, Losowky MS (1988) Sex hormones and chronic liver disease. J Hepatol 6:258–262
20. Kaymakoğlu S, Okten A, Cakaloğlu Y, Boztaş G, Beşişik F, Taşçioğlu C, Yalçin S (1995) Hypogonadism is not related to the etiology of liver cirrhosis. J Gastroenterol 30:745–750
21. Galvão-Teles A, Burke CW, Anderson DC, Marshall JC, Corker CS, Bown RL, Clark ML (1973) Biologically active androgens and oestradiol in men with chronic liver disease. Lancet 1:173–177
22. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocytes expression of Sost/sclerostin. J Biol Chem 293:5866–5875
23. Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S (1989) Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 96:213–221
24. Cemborain A, Castilla-Cortázar I, García M, Muguerza B, Delgado G, Díaz-Sánchez M, Picardi A (2000) Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis. J Physiol Biochem 56:91–99
25. Kawelke N, Bentmann A, Hackl N, Hager HD, Feick P, Geursen A, Singer MV, Nakchbandi IA (2008) Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J Bone Miner Res 23:1278–1286
26. Xu G, Niki T, Virtanen I, Rogiers V, De Bleser P, Geerts A (1997) Gene expression and synthesis of fibronectin isoforms in rat hepatic stellate cells. Comparison with liver parenchymal cells and skin fibroblasts. J Pathol 183:90–98
27. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Muñoz-Torres M (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97:234–241
28. Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE (2012) Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 97:3744–3750